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Abstract
Dengue virus has caused major problems for public health officials for decades
in tropical and subtropical countries. We construct a compartmental model that in-
cludes the risk of hospitalization and its impact on public health policies. The basic
reproductive number, R0, is computed, as well as a sensitivity analysis on R0 pa-
rameters and discuss the relevance in public health policies. The local and global
stability of the disease-free equilibrium is established. Numerical simulations are
performed to better determine future prevention/control strategies.
1 Introduction
Dengue is a vector-borne viral infection that inflicts substantial health, economic, and
social burden to more than 100 countries in tropical and subtropical regions around
the world [4]. Globalization, climate change, unplanned urbanization, and insufficient
mosquito control programs [17, 28], are among the complex factors that have contributed
∗CIMPA-Escuela de Matemática, Universidad de Costa Rica, San José, Costa Rica. E-Mail:
fabio.sanchez@ucr.ac.cr
†Department of Mathematics, University of California Davis, California, USA. E-Mail: jar-
royoe@ucdavis.edu
‡Escuela de Salud Pública, Universidad de Costa Rica, San José, Costa Rica. E-Mail:
paola.vasquez@ucr.ac.cr
1
ar
X
iv
:1
90
8.
02
91
3v
1 
 [q
-b
io.
PE
]  
8 A
ug
 20
19
RUNNING TITLE 2
to the geographic expansion and rise in the global incidence of a disease, that is now caus-
ing an estimated 390 million infections annually, of which an approximated 96 million
have clinical manifestations [3].
The highly anthropophilic Aedes aegyti mosquito, is the predominant vector [31] of
the four antigenically-distinct, but closely related, dengue viruses (DENV-1, DENV-2,
DENV-3, and DENV-4) [15], while Aedes albopictus is considered secondary and less
efficient in urban settings [33]. Each one of these serotypes generates a unique host im-
mune response to the infection [42], where infection with a particular serotype will confer
lifelong immunity to that strain, but only short-term cross-immunity between serotypes
[32]. In areas where dengue is endemic, different serotypes often co-circulate, therefore,
infections with heterologous DENV serotypes are common and can lead to an increased
risk of more severe clinical manifestations [29]. However, the broad clinical spectrum of
dengue infections [46] depends not only in the individual DENV infection history, but
in a variety of factors like age of the human host [21], host genetic susceptibility [8],
possible chronic diseases [46] as well as, in the specific DENV serotype and genotype
causing the infection [50].
After the bite of an infected mosquito, a large proportion of the individuals will be
asymptomatic, and a silent reservoir of crucial importance in the dynamics of dengue
spread [12]. Individuals that do experience symptoms the most common outcome is a
self-limiting febrile illness that does not progress to more severe forms, and do not need
admission to a hospital. However, many of them will be unable to develop their every
day activities, resulting in a major economic burden [9]. Those that evolve, and require
hospitalization show a variety of warning signs as constant and intense abdominal pain,
persisting vomiting, ascitis, pleural o pericardial effusion, mucosal bleeding, lethargy,
lipothymia, hepatomegaly, and progressive increase in the hematocrit [47]. The disease
can also progress to hemorrhagic and shock complications that can lead to death of the
patient, although rare [46]. It is estimated that each year, approximately 500,000 cases
require hospitalization [49], with the number of deaths globally increasing by 65.5%
between 2007 and 2017 (from 24,500 to 40,500 deaths) [35].
In Costa Rica, dengue has been a significant public health challenge since 1993,
when after more than 30 years of absence, autochthonous cases were reported on the
Pacific coast [25]. Since then, and despite efforts made, dengue infections have been
documented annually, with peaks of transmission observed seasonally (within the year)
and cyclical every 2-5 years. A total of 376,158 clinically suspected and confirmed cases
[26] have been reported to the Ministry of Health, of which more than 45,000 cases
have required hospital care [26, 7]. DENV-1, DENV-2 and DENV-3 have circulated the
country in different moments and 1,196 of the total of cases, have been classified as
severe dengue, which lead to 23 deaths [26].
Given the complexity involved in the transmission of vector borne diseases, such as
dengue, mathematical models play a significant role to better understand the interactions
between the vector, the virus and the host. In this article we develop a compartmental
model that analyses the effect of discriminating the hospitalized (diagnosed) infected in-
dividuals and its effectiveness on the overall behavior of the dynamics of dengue fever,
which can provide information for public health authorities to implement better preven-
tion and control approaches.
The article is divided in the following sections. In Section 2, we introduce a com-
partmental model that describes the transmission dynamics of dengue fever; Section 3,
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presents the results of the model; in Section 4, we give a discussion and concluding
remarks.
2 Model with risk of hospitalization
We introduce a model that describes the dynamics of dengue between hosts and vectors
in Costa Rica that includes the role of hospitalizations. According to data provided by the
Costa Rican Social Security Fund (CCSS), during the last two decades, a total of 45,577
patients with DENV infections, have required hospital care services [7], which represents
13% of the total of reported confirmed and suspected cases reported during that same
period. In Figure 1, we illustrate the concentration of hospitalizations due to the DENV in
the country. As seen in the map, the vast majority of hospitalized patients were reported
from regions near the coasts, where temperature is ideal for mosquito prevalence and
with circulation of the other two arboviruses, zika and chikungunya. Limón, a province
located in the Caribbean coast, reported a total of 17,894 hospitalized cases, follow by
Guanacaste with 12,233 cases and Puntarenas with 8,244 cases, both of them located in
the Pacific coast. Patients in the age group of 20-44 years of age represented the 43.8% of
the total of hospitalized patients and no significant difference between men and women
was observed [7].
(a) Dengue hospitalizations by region, Costa
Rica 1997-2017.
(b) Dengue hospitalizations by sex and age group, Costa Rica
1997-2017.
Figure 1: In Costa Rica, the vast majority of hospitalizations were reported in the coastal regions.
These areas, are characterized by been highly infested by the Aedes mosquito and by
having the higher incidence of dengue cases throughout the year [7].
Model state variables are presented in Table 1. The following is the system of non-
linear differential equations:
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(1)
S′h = µhNh − βhvSh IvNv − µhSh,
E′h = βhvSh
Iv
Nv
− (µh + αh)Eh,
I ′h = (1− p)αhEh − (µh + γ + δ)Ih,
H ′ = pαhEh + δIh − (µh + γ)H,
R′ = γIh + γH − µhR,
S′v = µvNv − βvhSv (Ih+(1−η)H)Nh−ηH − µvSv,
E′v = βvhSv
(Ih+(1−η)H)
Nh−ηH − (µv + αv)Ev,
I ′v = αvEv − µvIv,
where Nh = Sh + Eh + Ih + H + R and Nv = Sv + Ev + Iv and each variable is
described in Table 1 and their respective parameters in Table 2. The model diagram is
presented in Figure 2.
Table 1: Model variables.
State Variable Description
Sh Susceptible individuals
Eh Exposed individuals (infected but not infectious)
Ih Infected individuals
H Hospitalized individuals
R Recovered individuals
Sv Susceptible vectors
Ev Exposed vectors (infected but not infectious)
Iv Infected vectors
Table 2: Model parameters and description.
Parameter Description
βhv Transmission rate (host-vector)
βvh Transmission rate (vector-host)
αh Per capita exposed rate of humans
αv Per capita exposed rate of vectors
δ Per capita hospitalization rate after infection (undiagnosed)
γ Per capita recovery rate of humans
p Proportion of individuals being hospitalized (diagnosed)
η Effectiveness of hospitalization (dimensionless)
µh Per capita mortality rate of humans
µv Per capita mortality rate of vectors
We assume the host and mosquito remain constant in time, moreover we can have
the following re-scaled variables, sh = ShNh , eh =
Eh
Nh
, ih = IhNh , } =
H
Nh
, rh = RNh ,
sv =
Sv
Nv
, ev = EvNv , iv =
Iv
Nv
. Hence, the re-scaled system becomes:
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Figure 2: Model diagram.
(2)
s′h = µh − βhvshiv − µhsh,
e′h = βhvshiv − (µh + αh)eh,
i′h = (1− p)αheh − (µh + γ + δ)ih,
}′ = pαheh + δih − (µh + γ)},
r′ = γih + γ}− µhr,
s′v = µv − βvhsv (ih+(1−η)h)1−ηh − µvsv,
e′v = βvhsv
(ih+(1−η)h)
1−ηh − (µv + αv)ev,
i′v = αvev − µviv,
where sh + eh + ih + }+ r = 1 and sv + ev + iv = 1.
Theorem 1 The closed set Ω = {(sh, eh, ih, }, r, sv, ev, iv) ∈ <8+ : 0 < sh + eh + ih +
}+ r ≤ 1, 0 < sv +ev + iv ≤ 1} is positively invariant for model (2) and is absorbing.
Proof. Let x0 ∈ Ω be the initial state of System 2. To prove this theorem we will show
that if y = 0, then y′ ≥ 0, where y is any variable of the model. Assume first that y = 0,
then notice that, from the model we have that y′ = f(x)− yg(x), where x is the state of
the system and f, g are non-negative functions. Then it happens that y′ = f(x) ≥ 0 if
y = 0, therefore y ≥ 0.
Now, since sh + eh + ih + } + r = 1 and sv + ev + iv = 1 and from the previous
step all variables are non-negative, then all variables y satisfy that y ≤ 1.
Therefore Ω is a positively invariant set for the model.
Theorem 2 The system (2) has exactly one equilibrium point when there is no disease in
Ω ∈ <8+.
Proof. The local equilibria are the vectors (s∗h, e∗h, i∗h, }∗, r∗, s∗v, e∗v, i∗v) such that all of
the derivatives in System 2 are equal to 0. Some simple algebra leads us to the following
RUNNING TITLE 6
relation between exposed individuals on each population:
e∗h =
βhµhαv
µh + αh
e∗v
µhµv + βhαve∗v
,
where, if
Hˆ =
i∗h(1− η)}∗
1− η}∗ ,
then
e∗v
µhµv + βhαve∗v
,=
βvµv
µv + α
Hˆ
µv + Hˆβv
.
To turn this system into a single variable equation, notice that i∗h and }∗ satisfy the
following relationships:
}∗ =
φαhe
∗
h + δi
∗
h
µh + γ
,
i∗h =
(1− φ)αhe∗h
µh + γ + δ
.
By making those substitutions on Hˆ and simplifying, we get that:
Hˆ
µv + Hˆβv
=
e∗h∆i
M + e∗h(∆i −∆v)
,
where:
∆i = (1− φ)αh(µh + γ) + (1− η)φαh(µh + γ + δ) + (1− η)δ(1− φ)αh,
∆v = ηµvαh(µh + γ + δ) + ηµvδ(1− φ)αh,
M = µv(µh + γ)(µh + γ + δ).
If we let
Γh =
βhµhαv
µh + αh
,
Γv =
βvµv
µv + α
,
then we get the following equation:
e∗h =
ΓhΓv∆ie
∗
h
M + e∗h(∆i −∆v)
,
which has the following two solutions:
e∗h =0,
e∗h =
ΓhΓv∆i −M
∆i −∆v ,
(3)
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which correspond to the disease-free and endemic equilibrium points, respectively. If
we let e∗h as any of those values, by simplifying the other equations we get that:
s∗h =
1
kse∗h + 1
,
i∗h = kie
∗
h,
}∗ = k}e∗h,
r∗ = kre∗h,
s∗v =
1
1 + κse∗h
,
e∗v = κee
∗
h,
i∗v = κie
∗
h.
Where the k’s and κ’s are parameters. The case e∗h = 0 shows the existence of the
disease-free equilibrium point (1, 0, 0, 0, 0, 1, 0, 0).
3 Model results
In this section we perform the following analyses for System 2: R0 calculation, global
equilibria of disease free equilibrium, sensitivity analysis, and some numerical simula-
tions.
3.1 Basic reproductive number
We compute the basic reproductive number,R0, using the next generation operator [11].
We compute the F matrix where the entries include the transmission terms for both, the
host and vector populations,
F =

0 0 0 0 βhv
0 0 βvh βvh(1− η) 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0

and the V matrix that includes the infectious periods of both, the host and vector
populations.
V =

(µh + αh) 0 0 0 0
0 (µv + αv) 0 0 0
−αh(1− p) 0 (µh + γ + δ) 0 0
−pαh 0 −δ (µh + γ) 0
0 αv 0 0 µv

We then find V −1 and compute FV −1, where ρ represents the dominant eigenvalue,
and hence, the basic reproductive number is given by:
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R0 =
√
βhv
(µh + γ + δ)
βvh
µv
αh
(µh + αh)
αv
(µv + αv)
[
δ(1− η)
(µh + γ)
+ (1− ηp)
]
.
And can be broken down and interpreted as in Table 3.
Table 3: Basic reproductive number factors.
Number Description
βhv Transmission rate (host-vector)
αh
µh+αh
Probability an individual survives the exposed period
1
µh+γ+δ
Average human infectious period
βvh Transmission rate (vector-host)
αv
µv+αv
Probability a vector survives the exposed period
1
µv
Average vector infectious period
We define,
Ru = βhv
(µh + γ + δ)
βvh
µv
αh
(µh + αh)
αv
(µv + αv)
(1− ηp)
as the contribution of individuals that are infected and undiagnosed. And
Rd = βhv
(µh + γ + δ)
βvh
µv
αh
(µh + αh)
αv
(µv + αv)
δ(1− η)
(µh + γ)
as the contributions of individuals that are hospitalized and therefore diagnosed by de-
fault.
Therefore,R0 can be represented by the contributions of individuals that are undiag-
nosed and hospitalized (diagnosed), respectively. Hence,
R0 =
√
Ru +Rd.
3.2 Global equilibria
In this section we establish the global stability of the disease-free equilibrium using the
methods developed in [5].
Theorem 3 The disease-free equilibrium of System 2 is globally asymptotically stable if
R0 < 1.
Proof. Let X ∈ Rn be the uninfected individuals and Z ∈ Rm the infected individuals
in the system such that the System 2 is rewritten as:
dX
dt
=F (X,Z),
dZ
dt
=G(X,Z).
(4)
Then, if the three following conditions are met:
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1. R0 < 1
2. For dXdt = F (X, 0), the disease-free equilibrium X
∗ is globally asymptotically
stable.
3. G(X,Z) = AZ − Gˆ(X,Z), where A = GZ(X∗, 0) and Gˆ(X,Z) ≥ 0 for all
(X,Z) where the model makes sense.
Then the disease-free equilibrium is globally asymptotically stable.
In this section we will prove that conditions (2) and (3) are met by our model. First,
consider that X = (sh, r, sv) and Z = (eh, ih, }, ev, iv), then:
F (X,Z) =
 µh − βhvshiv − µhshγih + γ}− µhr
µv − βvhsv ih+(1−η)}1−η} − µvsv
 ,
G(X,Z) =

βhvshiv − (µh + αh)eh
(1− p)αheh − (µh + γ + δ)ih
pαheh + δih − (µh + γ)}
βvhsv
ih+(1−η)}
1−η} − (µv + αv)ev
αvev − µviv
 .
For verifying condition (2), note that:
F (X, 0) =
 µh − µhsh−µhr
µv − µvsv
 .
In this case, the equation:
dX
dt
= F (X, 0).
Has the solution:
X(t) =
 1 + e−µhe−µh
1 + e−µv

which satisfies that
lim
t→∞X(t) = (1, 0, 1) = X
∗.
Therefore the disease-free equilibrium X∗ is globally asymptotically stable and con-
dition (2) holds. For condition (3), consider the following matrix:
A =

−(µh + αh) 0 0 0 βhv
(1− p)αh −(µh + γ + δ) 0 0 0
pαh δ −(µh + γ) 0 0
0 βvh βvh(1− η) −(µv + αv) 0
0 0 0 αv −µv
 .
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Let:
Gˆ(X,Z) =

βhviv − βhvshiv
0
0
βvh(ih + (1− η)})− βvhsv ih+(1−η)}1−η}
0
 .
Note that sh ≤ 1 and sh1−η} ≤ 1, then Gˆ(X,Z) ≥ 0 for all (X,Z) ∈ Ω, where Ω is
given in Theorem (1). Then G(X,Z) = AZ − Gˆ(X,Z) and condition (3) follows.
3.3 Sensitivity analysis
For analyzing the sensitivity of our model, we compute the sensitivity indices of the
parameters with respect to R0 as described in [10]. These indices correspond to the
partial derivatives ofR0 with respect to each parameter evaluated on the baseline values
found in Table 4.
Table 4: Parameters for dengue with baseline values, range and references. Unit of time is days.
Parameter Baseline Range Reference
βhv 0.33 0.10− 0.75 [24]
βvh 0.33 0.10− 0.75 [24]
1/αh 5 4− 7 [24]
1/αv 10 7− 14 [24]
δ 0.20 0.10− 5 [39]
1/γ 6 4− 12 [24]
p 0.20 0− 1 estimated
η 0.80 0− 1 estimated
1/µh 70 68− 76 [10]
1/µv 14 8− 42 [24]
Table 5: Sensitivity indices forR0.
Parameter Sensitivity index
αh +0.2534
αv +3.1677
βhv +2.3038
βvh +2.3038
δ −1.2037
η −0.9352
γ −2.8710
µh −6.4188
µv −15.0783
p −0.5732
These indices give us an insight on which parameters affect in a more significant
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manner the value of R0. Notice the high negative value of the sensitivity index of the
mortality rate of the vector µv , which is biologically explained by the fact that as the rate
in which infected vectors are replaced by susceptible vectors grows, then the incidence
of infected hosts is reduced since there are less infected vectors.
Another important mention correspond to the indices of the hospitalization rate af-
ter infection, proportion of individuals being hospitalized, and effectiveness of hospi-
talization (δ, p, η respectively). Although the values of their indices are relatively low
compared to other parameters with negative indices, the parameters themselves can be
increased in a more reliable manner. This can be done through educating the population
on assisting to medical centers in a more frequent manner (for increasing p and δ) and
improving the sanitary conditions of hospitals (for increasing η). The values of these in-
dices, therefore let us understand how much can theR0 value be improved by increasing
these parameters, and therefore reducing the population infected by dengue.
Another tool to understand the sensibility of the R0 value is through the global un-
certainty quantification described in [24]. This quantification consists in developing an
empirical probability distribution for the R0 value by assuming the parameters follow
an uniform distribution in their ranges displayed in Table 4 and then performing random
samplings of those parameters and plugging them in the value of R0. The probability
distribution ofR0 obtained after 100,000 samples is displayed in Figure 3.
Figure 3: Probability distribution ofR0 after 100,000 samples.
As suggested by Figure 3, the most possible range for the R0 value lies between 0.5
and 2, which implies that in the case ofR0 > 1, it is likely that by performing tweaks in
the parameters (in a real context, that is promoting policies that alter in a real population
the values of the parameters of the model) we could reduce the value of R0 closer to 1
and thus significantly reduce the incidence of dengue in a human population.
3.4 Numerical scenarios for η and p
We explored numerical experiments in attempting to find the optimal effectiveness of
hospitalization of individuals. However, this is highly correlated with the number of
individuals who are hospitalized due to more acute symptoms and therefore diagnosed.
We can assume that the hospitalization of individuals is for the most part effective. More
specifically, in Costa Rica most hospitals have the adequate equipment and staff to attend
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these cases.
We explored numerical experiments in attempting to find the optimal effectiveness
of hospitalization of individuals. However, this is highly correlated with the number of
individuals who are hospitalized. In Costa Rica, depending on the clinical manifesta-
tions and different social determinants, patients are usually sent home with basic clinical
symptomatic care, recommendations, and schedule appointments in their local health
care establishments to monitor evolution. Patients can also be refereed for in-hospital
management or require emergency treatment and urgent referral [47, 6]. The average of
hospital stay among those that do require so, ranges between 3 and 4 days [23], with
more severe forms requiring longer stays.
Figures 4 and 5 refer to the evolution in the number of individuals infected non-
hospitalized and hospitalized, respectively.
Figure 4: Time series solutions of Infected (presumed undiagnosed) individuals, ih.
Figure 7 shows how the R0 value behaves as p and η changes, leaving all the other
parameters with their baseline values found on Table 4. Notice that numerical estima-
tions hint us that fixing the value of p and increasing the value of η lowers the R0 value
in a faster rate than by fixing the value of η and increasing the value of p. This finding re-
lates to the difference in the sensitivity indexes found in Table 5 and suggests that, based
on this model, increasing the effectiveness in hospitalization along with educating pa-
tients on preventing methods to minimize infecting others can potentially reduce dengue
incidence.
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Figure 5: Time series solutions of hospitalized (presumed diagnosed) individuals, }.
Figure 6: Time series solutions of infected vectors, Iv .
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(a)R0 versus p. (b)R0 versus η.
Figure 7: R0 versus the probability of hospitalization and effectiveness of hospitalization.
4 Discussion
In Costa Rica, as in most of the endemic countries, prevention and control strategies
have focused on vector control mainly through insecticides targeting at larval or adult
mosquitoes [27, 42]. The country, also follows the recommendations made by the World
Health Organization, to promote an strategic approach known as Integrated Vector Man-
agement [48]. However, despite these efforts its proper implementation has been difficult
to achieve and dengue continues to represent a mayor burden to the health care system.
Based on the results of our model, timely and context-specific dengue contingency
plans that involve providing a safer environment for those patients that stay home dur-
ing their treatments, hence preventing them from propagating the virus, should be one
of the priorities among public health officials. Year-round routine activities that involve
more active participation from members of the community is one of the strategies that
are increasingly being thought to be relevant for a successful control program [34, 2, 30].
Continuous capacity building in the communities will allow to reinforce local ownership,
where programs adapted to the specific social, economic, environmental and geographic
characteristics are a priority [41]. These strategies need to go in hand with better coordi-
nation and communication among institutions so that successful activities of one sector
will no be weakened by the lack of commitment from another. Also, because the clinical
symptoms of dengue are so diverse and the recent emergence of other two arboviruses,
each one with similar symptoms but different clinical outcomes, accurate clinical diag-
nosis is challenging. As such, training of health professional in diagnosis and manage-
ment in conjunction with laboratory and epidemiological surveillance, is essential [36].
Early accurate notifications of DENV infections will allow health officials to initialized
promptly and targeted responses, and continues to highlight the importance and urgent
need for the development of specific and sensitive point-of-care test for DENV infections
[20].
The intricacies involved in the transmission dynamics of vector-borne viruses, such as
the dengue virus, makes interdisciplinary collaboration essential to successfully achieve
more efficient prevention and control strategies. As dengue virus continues to spread
worldwide, the ever increasing need to develop and apply cost-effective, evidence-based
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approaches to identify and respond to potential outbreaks, has been one of the central
topics from many points of view, including mathematics and medical scientists. As part
of this collaboration, mathematical models have proven to be an increasingly valuable
tool for the decision making process of public health authorities [19].
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